30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
Our quarterly report takes a look back at the most significant class action developments over the la...
Read More >
Last week, the IRS issued it updated Form 1094-C and 1095-C instructions for 2019. Employers that em...
Read More >
Among the measures taken to face the emergency arising from COVID-19, the Italian Government adopted...
Read More >
As life under lockdown begins to feel like the 'new norm', we have created two snapshots of the key ...
Read More >
On July 17, 2019, the Internal Revenue Service (the “IRS”) released Notice 2019-45 which expands t...
Read More >
February 1 is the deadline for broadcast stations licensed to communities in Arkansas, Kansas, Louis...
Read More >